Intervention Protocol

Adenosine A2A receptor antagonist istradefylline for levodopa-induced complications in Parkinson's disease

  1. Yousheng Xiao,
  2. Lu Gan,
  3. Jin Wang*

Editorial Group: Cochrane Movement Disorders Group

Published Online: 14 MAR 2012

DOI: 10.1002/14651858.CD009709


How to Cite

Xiao Y, Gan L, Wang J. Adenosine A2A receptor antagonist istradefylline for levodopa-induced complications in Parkinson's disease (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 3. Art. No.: CD009709. DOI: 10.1002/14651858.CD009709.

Author Information

  1. The First Affiliated Hospital, Guangxi Medical University, Department of Neurology, Nanning, Guangxi, China

*Jin Wang, Department of Neurology, The First Affiliated Hospital, Guangxi Medical University, No. 22, Shuang Yong Lu, Nanning, Guangxi, 530021, China. wangjin72@126.com.

Publication History

  1. Publication Status: New
  2. Published Online: 14 MAR 2012

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the efficacy and safety of adjuvant istradefylline therapy versus placebo in PD patients with levodopa-induced complications.